Docker, Natural Language Processing (NLP), Python Programming, PyTorch, SQL
OPPORTUNITY
We are currently seeking an Associate Scientist/Scientist I to conduct gene editing translational research within the growing Technology Validation group at Mammoth Biosciences. This individual will make significant contributions to several projects within Mammoth’s early-stage therapeutics pipeline. Specifically, the candidate will be responsible for adapting new technologies developed by our engineering teams to therapeutically-relevant protocols developed by our therapeutic teams, including routine gene editing of primary cells and cell lines, and occasional development of fit-for-purpose characterization assays. The ideal candidate will have a foundation in gene editing research, assay development experience, and the ability to rapidly learn and adapt as our platforms evolve. They will gain hands-on experience with a diverse set of gene editing tools, and the opportunity to interface with Mammoth Therapeutics teams across multiple disciplines related to therapeutics development.
KEY RESPONSIBILITIES
REQUIRED QUALIFICATIONS
PREFERRED QUALIFICATIONS
BENEFITS
Base Salary Range: $105,678 - $131,250
The listed base salary range is for Mammoth employees in the Bay Area. Actual base salary will be determined by geographic work location, relevant professional experience, applicable skills, and internal equity. The base salary range for those working remotely outside of the San Francisco Bay Area may differ and will be determined by industry market data for the role and specific region.
COMPANY
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple condition